Allison Bratzel
Stock Analyst at Piper Sandler
(3.71)
# 746
Out of 4,749 analysts
33
Total ratings
66.67%
Success rate
22.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Overweight | $620 → $725 | $654.76 | +10.73% | 13 | Jan 7, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $20.45 | +7.58% | 2 | Nov 14, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $23 | $22.49 | +2.27% | 2 | Nov 14, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $65 → $62 | $32.88 | +88.56% | 1 | Nov 14, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $28 → $42 | $42.56 | -1.32% | 3 | Oct 15, 2024 | |
| ROIV Roivant Sciences | Maintains: Overweight | $20 → $22 | $11.13 | +97.66% | 2 | Jul 10, 2024 | |
| HUMA Humacyte | Maintains: Neutral | $4 | $4.56 | -12.28% | 2 | Mar 26, 2024 | |
| SLDB Solid Biosciences | Upgrades: Overweight | $8 → $20 | $3.33 | +500.60% | 4 | Mar 14, 2024 | |
| ABCL AbCellera Biologics | Assumes: Overweight | $20 | $3.20 | +525.00% | 1 | Oct 13, 2023 | |
| REPL Replimune Group | Assumes: Overweight | $44 | $14.07 | +212.72% | 1 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $73.72 | +35.65% | 2 | Feb 8, 2023 |
argenx SE
Jan 7, 2025
Maintains: Overweight
Price Target: $620 → $725
Current: $654.76
Upside: +10.73%
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $20.45
Upside: +7.58%
Rigel Pharmaceuticals
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $22.49
Upside: +2.27%
Ionis Pharmaceuticals
Nov 14, 2024
Maintains: Overweight
Price Target: $65 → $62
Current: $32.88
Upside: +88.56%
Scholar Rock Holding
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $42.56
Upside: -1.32%
Roivant Sciences
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $11.13
Upside: +97.66%
Humacyte
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $4.56
Upside: -12.28%
Solid Biosciences
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $3.33
Upside: +500.60%
AbCellera Biologics
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $3.20
Upside: +525.00%
Replimune Group
Apr 17, 2023
Assumes: Overweight
Price Target: $44
Current: $14.07
Upside: +212.72%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $73.72
Upside: +35.65%